HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro and in vivo activity of DQ-2556, a new cephalosporin.

Abstract
The antibacterial activity of DQ-2556, a new cephalosporin, was compared with that of cefepime, cefpirome, and other antibiotics. DQ-2556 was more active than cefepime and less active than cefpirome against gram-positive bacteria. DQ-2556 was the most active compound against most members of the Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella spp., and Shigella spp., and Haemophilus influenzae and Neisseria gonorrhoeae. In vivo, treatment with DQ-2556 was as or more efficacious than that with reference compounds in both systemic and respiratory tract infections in mice. DQ-2556 achieved higher concentrations than cefepime and cefpirome in lungs and kidney of mice.
AuthorsY Ishida, S Miyazaki, K Yamaguchi, S Goto
JournalChemotherapy (Chemotherapy) 1995 Jan-Feb Vol. 41 Issue 1 Pg. 5-13 ISSN: 0009-3157 [Print] Switzerland
PMID7875022 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Cephalosporins
  • DQ 2556
Topics
  • Animals
  • Bacteria (drug effects)
  • Bacterial Infections (drug therapy)
  • Cephalosporins (administration & dosage, pharmacokinetics, pharmacology)
  • Enterobacteriaceae (drug effects)
  • Lung Diseases (drug therapy)
  • Male
  • Mice
  • Microbial Sensitivity Tests

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: